New drug cocktail aims to outsmart lung cancer

NCT ID NCT07005102

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times

Summary

This study tests whether adding an experimental drug called telisotuzumab adizutecan to the standard targeted therapy osimertinib can improve outcomes for people with advanced EGFR-mutated non-small cell lung cancer. About 854 adults will be enrolled worldwide. The trial has two stages: first to find the best dose, then to compare the combo against standard care (osimertinib plus chemotherapy). The main goals are to see if the combo shrinks tumors and delays cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AZ-Delta. /ID# 275753
RECRUITING

Roeselare, West-Vlaanderen, 8800, Belgium
Asan Medical Center /ID# 275600
RECRUITING

Seoul, Seoul Teugbyeolsi, 05505, South Korea
Austin Health /ID# 275505
RECRUITING

Heidelberg, Victoria, 3084, Australia
Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 275215
RECRUITING

Orbassano, Torino, 10043, Italy
CHU de Liege /ID# 277971
RECRUITING

Liège, 4000, Belgium
Chungbuk National University Hospital /ID# 275768
RECRUITING

Cheongju-si, North Chungcheong, 28644, South Korea
Hospital Clinic de Barcelona /ID# 275476
RECRUITING

Barcelona, 08036, Spain
Hospital Cuf Porto /ID# 275395
RECRUITING

Porto, 4100-180, Portugal
Hospital General Universitario Gregorio Maranon /ID# 275475
RECRUITING

Madrid, 28007, Spain
Hospital Universitario 12 de Octubre /ID# 277698
RECRUITING

Madrid, 28041, Spain
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 274948
RECRUITING

Rome, Roma, 00144, Italy
Inje University Haeundae Paik Hospital /ID# 275388
RECRUITING

Busan, Busan Gwang Yeogsi, 48108, South Korea
Instituto Valenciano de Oncología /ID# 275471
RECRUITING

Valencia, 46009, Spain
Ironwood Cancer and Research Centers - Chandler II /ID# 275443
RECRUITING

Chandler, Arizona, 85224, United States
Jessa Ziekenhuis - Campus Virga Jesse /ID# 275585
RECRUITING

Hasselt, Limburg, 3500, Belgium
Juntendo University Hospital /ID# 276424
RECRUITING

Bunkyo-ku, Tokyo, 113-8431, Japan
Kaiser Permanente Moanalua Medical Center /ID# 275942
RECRUITING

Honolulu, Hawaii, 96819, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 275293
RECRUITING

Kaohsiung City, 807, Taiwan
Liverpool Hospital /ID# 276304
RECRUITING

Liverpool, New South Wales, 2170, Australia
Mid Florida Hematology And Oncology Center /ID# 275278
RECRUITING

Orange City, Florida, 32763, United States
National Cancer Center Hospital /ID# 275678
RECRUITING

Chuo-Ku, Tokyo, 104-0045, Japan
National Cancer Centre Singapore /ID# 275986
RECRUITING

Singapore, Central Singapore, 169611, Singapore
National Taiwan University Cancer Center (Ntucc) /ID# 275291
RECRUITING

Taipei, 106, Taiwan
National University Hospital /ID# 275988
RECRUITING

Singapore, 119074, Singapore
Nho - Revive Research Institute /ID# 276115
RECRUITING

Lincoln, Nebraska, 68506, United States
Niigata University Medical and Dental Hospital /ID# 275685
RECRUITING

Niigata, Niigata, 951-8520, Japan
Osaka Medical And Pharmaceutical University Hospital /ID# 275684
RECRUITING

Takatsuki, Osaka, 569-8686, Japan
Princess Margaret Cancer Centre /ID# 274845
COMPLETED

Toronto, Ontario, M5G 2M9, Canada
Rabin Medical Center. /ID# 274540
RECRUITING

Petah Tikva, Central District, 4941492, Israel
Rambam Health Care Campus- Haifa /ID# 274542
RECRUITING

Haifa, 3109601, Israel
Renown Regional Medical Center /ID# 276049
RECRUITING

Reno, Nevada, 89502, United States
Samsung Medical Center /ID# 278083
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
Shizuoka Cancer Center /ID# 278082
RECRUITING

Sunto-gun, Shizuoka, 411-8777, Japan
St John Of God Murdoch Hospital /ID# 275700
RECRUITING

Murdoch, Western Australia, 6150, Australia
Taipei Veterans General Hospital /ID# 275292
RECRUITING

Taipei, 112, Taiwan
Texas Oncology - Palestine Cancer Center /ID# 276034
RECRUITING

Palestine, Texas, 75801, United States
Texas Oncology - South Austin /ID# 276033
RECRUITING

Austin, Texas, 78745, United States
The Chaim Sheba Medical Center /ID# 274541
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
The Iowa Clinic /ID# 276020
COMPLETED

West Des Moines, Iowa, 50266, United States
The Ottawa Hospital - General Campus /ID# 275611
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
The Queen Elizabeth Hospital /ID# 275719
RECRUITING

Woodville, South Australia, 5011, Australia
The University of Texas MD Anderson Cancer Center /ID# 275107
RECRUITING

Houston, Texas, 77030, United States
USC Norris Comprehensive Cancer Center /ID# 275343
RECRUITING

Los Angeles, California, 90033, United States
Unidade Local de Saude de Braga, EPE /ID# 275394
RECRUITING

Braga, 4710-243, Portugal
Unidade Local de Saude de Santo Antonio /ID# 275387
RECRUITING

Porto, 4099-003, Portugal
Union Hospital Tongji Medical College /ID# 278711
RECRUITING

Wuhan, Hubei, 430048, China
Universitair Ziekenhuis Leuven /ID# 275586
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
University Colorado Cancer Center /ID# 275382
RECRUITING

Aurora, Colorado, 80045-2517, United States
University of Washington Medical Center /ID# 275866
RECRUITING

Seattle, Washington, 98195, United States
Usc Norris Oncology/Hematology Treatment Center /ID# 278673
RECRUITING

Newport Beach, California, 92663, United States
Virginia Cancer Specialists - Fairfax /ID# 275071
RECRUITING

Fairfax, Virginia, 22031, United States
Yokohama Municipal Citizen's Hospital /ID# 275682
RECRUITING

Yokohama, Kanagawa, 221-0855, Japan
Yonsei University Health System Severance Hospital /ID# 275384
RECRUITING

Seoul, Seoul Teugbyeolsi, 03722, South Korea

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Telisotuzumab adizutecan (an investigational antibody-drug conjugate) combined with osimertinib (a targeted therapy)

What this could lead to

If successful, this combination could offer a more effective first-line treatment option for people with a specific type of advanced lung cancer, potentially delaying disease progression.

What could go wrong

This is an early-to-mid stage trial (phase 2/3) testing an investigational drug. The combination may cause more side effects than standard care, and it's not yet proven to be better or safe long-term.

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER